HYRNUO

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
HYRNUO
Generic name
SEVABERTINIB
Manufacturer
Bayer HealthCare Pharmaceuticals Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
d7a11334-6e7a-445b-9a16-bdcd9acbe61f
SPL ID
2ba86679-0db2-44b4-86d1-e69413e24762
Version
10
Effective date
2026-09-17
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:02:02
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Diarrhea : At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment, and to increase their fluid and electrolyte intake. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.1 ) Hepatotoxicity : Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to the first administration of HYRNUO, every 2 weeks for the first month, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.2 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Discontinue HYRNUO upon confirmation of ILD/pneumonitis. ( 5.3 ) Left Ventricular Dysfunction : Evaluate LVEF prior to initiation of HYRNUO and monitor at regular intervals during treatment and as clinically indicated. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.4 ) Ocular Toxicity : Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.5 ) Pancreatic Enzyme Elevation : Monitor amylase and lipase regularly during treatment. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity. ( 5.6 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. ( 5.7 , 8.1 , 8.3 ) 5.1 Diarrhea HYRNUO can cause severe diarrhea that can lead to dehydration and electrolyte imbalances. In the pooled safety population [see Adverse Reactions (6.1) ] , diarrhea was reported in 89% of patients who received HYRNUO including 16% Grade 3. The median time to first onset of any grade diarrhea was four days. Dosage interruptions occurred in 15% of patients, and dose reductions occurred in 14% of patients. At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment (e.g., loperamide [refer to full Prescribing Information] ), and to increase their fluid and electrolyte intake. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity [see Dosage and Administration (2.3) ] . 5.2 Hepatotoxicity HYRNUO can cause severe hepatotoxicity characterized by elevations of liver function tests. In the pooled safety population [see Adverse Reactions (6.1) ], based on adverse reaction data, hepatotoxicity occurred in 29% of patients treated with HYRNUO, including 3.1% Grade 3 and 0.3% Grade 4. Based on laboratory data, 41% of patients treated with HYRNUO experienced increased alanine aminotransferase (ALT), including 2.5% Grade 3 and 0.4% Grade 4. Increased aspartate aminotransferase (AST) occurred in 44% of patients treated with HYRNUO, including 2.5% Grade 3. Increased bilirubin occurred in 15% of patients treated with HYRNUO. The median time to first onset of AST or ALT elevation was 1.4 (range 0.2 to 24.1) months. HYRNUO was interrupted for an adverse reaction of hepatotoxicity in 4.2% of patients, the dose was reduced in 4.9% and permanently discontinued in 0.3%. Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to the first administration of HYRNUO, every 2 weeks for the first month, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity [see Dosage and Administration (2.3) ] . 5.3 Interstitial Lung Disease/Pneumonitis HYRNUO can cause severe interstitial lung disease (ILD)/pneumonitis. In the pooled safety population [see Adverse Reactions (6.1) ], ILD/pneumonitis occurred in four patients (1.4%) treated with HYRNUO, including 0.3% Grade 3. One patient required interruption of HYRNUO. Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Discontinue HYRNUO upon confirmation of ILD/pneumonitis [see Dosage and Administration (2.3) ] . 5.4 Left Ventricular Dysfunction HYRNUO can cause severe left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has occurred with anti-HER2 therapies, including HYRNUO. Treatment with HYRNUO has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment. In the pooled safety population [see Adverse Reactions (6.1) ], LVEF decrease occurred in one patient (0.3%) treated with HYRNUO. This Grade 3 LVEF decrease required permanent discontinuation of HYRNUO, and the event recovered. Evaluate LVEF prior to initiation of HYRNUO and monitor at regular intervals during treatment and as clinically indicated. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity [see Dosage and Administration (2.3) ]. 5.5 Ocular Toxicity HYRNUO can cause ocular toxicity. In the pooled safety population [see Adverse Reactions (6.1) ], ocular toxicity occurred in 17% of patients treated with HYRNUO, including 11% Grade 1, 4.9% Grade 2 and 0.3% Grade 3 (one case of corneal epithelial microcysts with temporary unilateral blindness). Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity [see Dosage and Administration (2.3) ]. 5.6 Pancreatic Enzyme Elevation HYRNUO can cause elevations of amylase and lipase levels . In the pooled safety population [see Adverse Reactions (6.1) ] , based on laboratory data, increased amylase occurred in 39% of patients treated with HYRNUO, including 3.9% Grade 3 and 0.7% Grade 4. Increased lipase occurred in 48% of patients treated with HYRNUO, including 13% Grade 3 and 1.1% Grade 4. Four patients (1.4%) required interruption of HYRNUO due to increased lipase and 3 (1%) required interruption of HYRNUO due to increased amylase. One patient (0.3%) required dose reduction of HYRNUO due to increased amylase. The median time to onset of increased amylase/lipase was 0.7 months (range 0.2 to 20.4 months). Monitor amylase and lipase regularly during treatment with HYRNUO. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity [see Dosage and Administration (2.3) ]. 5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, HYRNUO can cause fetal harm when administered to a pregnant woman. In embryo-fetal development studies, oral administration of sevabertinib to pregnant rats during the period of organogenesis resulted in alterations to growth at maternal exposures ≥0.18 times the human exposure based on area under the curve (AUC) at the clinical dose of 20 mg twice daily. Animal studies with disrupted or depleted HER2/EGFR and in vitro assays have demonstrated that inhibition of HER2 and/or EGFR results in structural abnormalities, alteration to growth, and embryo-fetal and infant mortality. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with HYRNUO and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with HYRNUO and for 1 week after the last dose [see Use in Specific Populations (8.1 , 8.3) ] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Diarrhea [see Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.3) ] Left Ventricular Dysfunction [see Warnings and Precautions (5.4) ] Ocular Toxicity [see Warnings and Precautions (5.5) ] Pancreatic Enzyme Elevation [see Warnings and Precautions (5.6) ] Most common (>20%) adverse reactions : diarrhea, rash, paronychia, nausea, vomiting and stomatitis. ( 6.1 ) Most common (≥2%) Grade 3 or 4 laboratory abnormalities : decreased potassium, increased lipase, decreased phosphate, decreased lymphocyte count, decreased sodium, increased amylase, decreased hemoglobin, increased ALT, increased AST and decreased calcium. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population in the WARNINGS AND PRECAUTIONS reflects exposure to HYRNUO at 20 mg orally twice daily in 287 patients with locally advanced or metastatic NSCLC harboring HER2 activating and/or other mutations from the SOHO-01 study [see Clinical Studies (14) ] . Among 287 patients who received HYRNUO, 61% were exposed for greater than 6 months and 37% were exposed for greater than 1 year. In this pooled safety population, the most common (>20%) adverse reactions were diarrhea, rash, paronychia, nausea, vomiting, and stomatitis. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased potassium, increased lipase, decreased phosphate, decreased lymphocyte count, decreased sodium, increased amylase, decreased hemoglobin, increased ALT, increased AST, and decreased calcium. Locally Advanced or Metastatic Non-squamous NSCLC whose tumors have HER2 (ERBB2) TKD Activating Mutations The safety of HYRNUO at 20 mg orally twice daily was evaluated in 191 patients with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations in the SOHO-01 study [see Clinical Studies (14) ] . The safety population included treatment naïve patients (Group F, N=69), previously treated patients naïve to HER2-targeted therapy (Group D, N=70), and previously treated patients with documented progression on HER2-targeted antibody drug conjugates (ADCs) (Group E, N=52). Among 191 patients who received HYRNUO, 66% were exposed for greater than 6 months and 43% were exposed for greater than 1 year. The median age of patients who received HYRNUO was 62 years (range: 29 to 91); 65% female; 68% Asian, 26% White, 2.1% Black or African American; and 1.6% were of Hispanic or Latino ethnicity. Serious adverse reactions occurred in 33% of patients who received HYRNUO. Serious adverse reactions in ≥2% of patients were diarrhea (3.7%), dyspnea (3.1%), vomiting (3.7%), pneumonia (2.6%), and pleural effusion (2.1%). A fatal adverse reaction of cerebral infarction occurred in one patient (0.5%) who received HYRNUO. Permanent discontinuation of HYRNUO due to an adverse reaction occurred in 4.2% of patients. Adverse reactions which resulted in permanent discontinuation were corneal epithelial microcysts, hepatic function abnormal, increased blood alkaline phosphatase, electrocardiogram QT prolonged, pain in extremity, renal failure and dyspnea (0.5%, 1 patient each). Dosage interruptions of HYRNUO due to an adverse reaction occurred in 49% of patients. Adverse reactions which resulted in dosage interruptions in >2% of patients were diarrhea, potassium decreased, hepatotoxicity, nausea, vomiting, rash, pneumonia, paronychia, decreased appetite, pruritus, acute kidney injury, and stomatitis. Dose reductions of HYRNUO due to adverse reactions occurred in 32% of patients. Adverse reactions which resulted in dose reductions in >2% of patients were diarrhea, hepatotoxicity, rash, potassium decrease, stomatitis, vomiting, and decreased appetite. Table 4 summarizes the adverse reactions in SOHO-01 (Groups D, E and F). Table 4: Adverse Reactions (≥15%) in Patients with NSCLC with HER2 Activating Mutations who Received HYRNUO in SOHO-01 (Groups D, E and F) Adverse Reaction Graded per NCI CTCAE version 5. HYRNUO N = 191 All Grades (%) Grade 3 or 4 No Grade 4 were reported. (%) Gastrointestinal disorders Diarrhea Grouped term. 90 14 Stomatitis 37 1 Nausea 22 2.1 Vomiting 19 4.2 Skin and subcutaneous tissue disorders Rash 76 1.6 Paronychia 36 1 Dry skin 18 0 Pruritus 16 1 Investigations Weight decreased 22 0.5 Metabolism and nutrition disorders Decreased appetite 19 2.6 Musculoskeletal and connective tissue disorders Musculoskeletal pain 18 0 General disorders and administration site conditions Fatigue 17 2.6 Eye disorders Ocular toxicity 16 0.5 Clinically relevant adverse reactions in <15% of patients who received HYRNUO included abdominal pain (14%), cardiac arrhythmia (10%; including arrhythmia, atrial fibrillation, atrial tachycardia, atrioventricular block complete, atrioventricular block first degree, electrocardiogram QT prolonged, sinus arrhythmia, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, supraventricular tachycardia, tachycardia, and ventricular extrasystoles) and alopecia (7%). Table 5 summarizes the laboratory abnormalities in SOHO-01 (Groups D, E and F). Table 5: Select Laboratory Abnormalities (≥20%) that Worsened from Baseline in Patients with NSCLC with HER2 Activating Mutations in SOHO-01 (Groups D, E and F) Laboratory Abnormality HYRNUO N=191 The denominator used to calculate the rate varied from 153 to 189 based on the number of patients with a baseline value and at least one post-treatment value. All Grades (%) Graded per NCI CTCAE version 5 using only numeric values. Grade 3 or 4 (%) Chemistry Lipase increased 53 18 Potassium decreased 51 18 Aspartate aminotransferase increased 46 2.6 No Grade 4 were reported. Glucose increased Graded per NCI CTCAE version 4.03 using only numeric values. 45 0.5 Alanine aminotransferase increased 43 3.2 Magnesium decreased 41 0 Amylase increased 39 5 Calcium decreased 36 1.6 Phosphate decreased 35 13 Sodium decreased 33 5 Creatinine increased 33 1.1 Albumin decreased 33 1.1 Triglycerides increased 33 0 Alkaline phosphatase increased 25 0.5 Hematology Hemoglobin decreased 52 3.7 Lymphocyte count decreased 29 4.6 White blood cell decreased 20 1.1 Laboratory abnormalities in <20% of patients who received HYRNUO include bilirubin increased (19%; all were Grades 1 and 2), platelet count decreased and neutrophil count decreased (16% each).

adverse reactions table

<table width="80%"> <caption>Table 4: Adverse Reactions (&#x2265;15%) in Patients with NSCLC with HER2 Activating Mutations who Received HYRNUO in SOHO-01 (Groups D, E and F)</caption> <col width="50%" align="left" valign="middle"/> <col width="25%" align="center" valign="middle"/> <col width="25%" align="center" valign="middle"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" rowspan="2">Adverse Reaction<footnote>Graded per NCI CTCAE version 5.</footnote> </th> <th styleCode="Rrule" colspan="2">HYRNUO N = 191</th> </tr> <tr styleCode="Botrule"> <th styleCode="Rrule" align="center">All Grades (%)</th> <th styleCode="Rrule">Grade 3 or 4<footnote>No Grade 4 were reported.</footnote> (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Gastrointestinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea<footnote ID="t4ft1">Grouped term.</footnote> </td> <td styleCode="Rrule">90</td> <td styleCode="Rrule">14</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Stomatitis<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">37</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Nausea</td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">2.1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Vomiting<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">4.2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Skin and subcutaneous tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Rash<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">76</td> <td styleCode="Rrule">1.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Paronychia<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">36</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Dry skin<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">18</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pruritus</td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> <content styleCode="bold">Investigations</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Weight decreased</td> <td styleCode="Rrule">22</td> <td styleCode="Rrule">0.5</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> <content styleCode="bold">Metabolism and nutrition disorders</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Decreased appetite</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">2.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Musculoskeletal pain<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">18</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">General disorders and administration site conditions</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Fatigue<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">17</td> <td styleCode="Rrule">2.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" colspan="3"> <content styleCode="bold">Eye disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule"> Ocular toxicity<footnoteRef IDREF="t4ft1"/> </td> <td styleCode="Rrule">16</td> <td styleCode="Rrule">0.5</td> </tr> </tbody> </table>

adverse reactions table

<table width="80%"> <caption>Table 5: Select Laboratory Abnormalities (&#x2265;20%) that Worsened from Baseline in Patients with NSCLC with HER2 Activating Mutations in SOHO-01 (Groups D, E and F)</caption> <col width="50%" align="left" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <thead> <tr styleCode="Botrule"> <th styleCode="Lrule Rrule" rowspan="2" valign="middle">Laboratory Abnormality</th> <th styleCode="Rrule" colspan="2" valign="bottom">HYRNUO N=191<footnote>The denominator used to calculate the rate varied from 153 to 189 based on the number of patients with a baseline value and at least one post-treatment value.</footnote> </th> </tr> <tr styleCode="Botrule"> <th styleCode="Rrule" align="center" valign="middle">All Grades (%)<footnote>Graded per NCI CTCAE version 5 using only numeric values.</footnote> </th> <th styleCode="Rrule" valign="middle">Grade 3 or 4 (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> <content styleCode="bold">Chemistry</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Lipase increased</td> <td styleCode="Rrule">53</td> <td styleCode="Rrule">18</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Potassium decreased</td> <td styleCode="Rrule">51</td> <td styleCode="Rrule">18</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Aspartate aminotransferase increased</td> <td styleCode="Rrule">46</td> <td styleCode="Rrule">2.6<footnote ID="t5ft1">No Grade 4 were reported.</footnote> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Glucose increased<footnote ID="t5ft3">Graded per NCI CTCAE version 4.03 using only numeric values.</footnote> </td> <td styleCode="Rrule">45</td> <td styleCode="Rrule">0.5<footnoteRef IDREF="t5ft1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Alanine aminotransferase increased</td> <td styleCode="Rrule">43</td> <td styleCode="Rrule">3.2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Magnesium decreased</td> <td styleCode="Rrule">41</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Amylase increased</td> <td styleCode="Rrule">39</td> <td styleCode="Rrule">5</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Calcium decreased</td> <td styleCode="Rrule">36</td> <td styleCode="Rrule">1.6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Phosphate decreased<footnoteRef IDREF="t5ft3"/> </td> <td styleCode="Rrule">35</td> <td styleCode="Rrule">13</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Sodium decreased<footnoteRef IDREF="t5ft3"/> </td> <td styleCode="Rrule">33</td> <td styleCode="Rrule">5<footnoteRef IDREF="t5ft1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Creatinine increased</td> <td styleCode="Rrule">33</td> <td styleCode="Rrule">1.1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Albumin decreased</td> <td styleCode="Rrule">33</td> <td styleCode="Rrule">1.1<footnoteRef IDREF="t5ft1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Triglycerides increased</td> <td styleCode="Rrule">33</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Alkaline phosphatase increased</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">0.5<footnoteRef IDREF="t5ft1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> <content styleCode="bold">Hematology</content> </td> <td styleCode="Rrule"/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Hemoglobin decreased</td> <td styleCode="Rrule">52</td> <td styleCode="Rrule">3.7<footnoteRef IDREF="t5ft1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Lymphocyte count decreased</td> <td styleCode="Rrule">29</td> <td styleCode="Rrule">4.6</td> </tr> <tr> <td styleCode="Lrule Rrule"> White blood cell decreased</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">1.1<footnoteRef IDREF="t5ft1"/> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.